Helius Medical Technologies to Release Third Quarter of Fiscal Year 2020 Financial Results on November 12, 2020GlobeNewsWire • 11/02/20
Helius Medical Technologies Announces Closing of $3.4 Million Private PlacementGlobeNewsWire • 10/26/20
Helius Medical Technologies, Inc. Provides Update on FDA's Review of its Request for De Novo Classification and Clearance of the PoNS™ Device for the Treatment of Gait Deficit Due to Symptoms of Multiple SclerosisGlobeNewsWire • 10/19/20
Helius Medical Technologies, Inc. Announces Partnership with Breakthrough Health for Multiple Sclerosis InsightsGlobeNewsWire • 10/14/20
Helius Medical Technologies, Inc. Announces Formation of Multiple Sclerosis Scientific Advisory BoardGlobeNewsWire • 10/08/20
Helius Medical Technologies, Inc. Announces Publication of Peer-Reviewed Study: Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS™) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-ModeratGlobeNewsWire • 09/08/20
Helius Medical Technologies, Inc. to Present at Three Upcoming Investor Conferences in SeptemberGlobeNewsWire • 08/31/20
Helius Medical Technologies, Inc. Announces Departure of President, Chief Executive Officer and Chairman Philippe Deschamps; Board of Directors Appoints Dane C.GlobeNewsWire • 08/25/20
Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/13/20
Helius Medical Technologies, Inc. Reports Second Quarter of Fiscal Year 2020 Financial ResultsGlobeNewsWire • 08/12/20
Helius Medical Technologies to Release Second Quarter of Fiscal Year 2020 Financial Results on August 12, 2020GlobeNewsWire • 08/10/20
Helius Medical Technologies, Inc. (HSDT) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/06/20
Helius Medical Technologies, Inc. Submits Request for FDA Clearance for PoNS™ Device; Reports Preliminary Financial Results for the Second Quarter and Six Months Ended June 30, 2020GlobeNewsWire • 08/06/20
Helius Medical Technologies Announces the Dismissal of the Shareholder Class Action LawsuitGlobeNewsWire • 07/14/20
Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple SclerosisGlobeNewsWire • 05/12/20
Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/11/20
UPDATE -- Helius Medical Technologies, Inc. Announces Publication of its PoNS™ Registrational Clinical Trial (TBI-001) in TBIGlobeNewsWire • 04/30/20
Helius Medical Technologies, Inc. Announces Publication of its PoNS™ Registrational Clinical Trial (TBI-001) in TBIGlobeNewsWire • 04/30/20
Helius Medical Technologies Appoints Jeffrey S. Mathiesen to its Board of DirectorsGlobeNewsWire • 04/22/20
Helius Medical Technologies Announces Authorization from Health Canada to Market the PoNS™ Device for the Treatment of Gait Deficit Due to Mild and Moderate Multiple Sclerosis (MS)GlobeNewsWire • 03/24/20
Helius Medical Technologies Announces $2.2 Million Registered Direct OfferingGlobeNewsWire • 03/18/20
Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/13/20
Helius Medical Technologies, Inc. Provides Details on Five Recently Authorized PoNS Treatment™ ClinicsGlobeNewsWire • 03/09/20
Helius Medical Technologies Reports Preliminary Unaudited Fourth Quarter and Full Year Unaudited 2019 Financial Results, Provides Commercial and Regulatory Update and Announces Submission to Health Canada for Multiple Sclerosis (MS) Label Expansion and NeGlobeNewsWire • 03/02/20